Josep Dalmau

ICREA-IDIBAPS

Grupo de investigación

Patogénesis de las enfermedades neuronales autoinmunes Group leader (R4)

jdalmau@clinic.cat 0000-0001-5856-2813

Publicaciones destacadas

Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders

Autores:
Guasp, Mar; Rosa-Justicia, Mireia; Munoz-Lopetegi, Amaia; Martinez-Hernandez, Eugenia; Armangue, Thais;

(...)

Llufriu, Sara; Sanchez-Valle, Raquel; Santamaria, Joan; Castro-Fornielest, Josefina; Dalmau, Josep.

Referencia: Lancet Neurology 2022.
Human CASPR2 Antibodies Reversibly Alter Memory and the CASPR2 Protein Complex

Autores:
Joubert, Bastien; Petit-Pedrol, Mar; Planaguma, Jesus; Mannara, Francesco; Radosevic, Marija;

(...)

Gasull, Xavier; Loza-Alvarez, Pablo; Sabater, Lidia; Rosenfeld, Myrna R; Dalmau, Josep.

Referencia: Annals Of Neurology 2022.
Neurofilament light chain levels in anti-NMDAR encephalitis and primary psychiatric psychosis

Autores:
Guasp, Mar; Martin-Aguilar, Lorena; Sabater, Lidia; Bioque, Miquel; Armangue, Thais;

(...)

Castro-Fornieles, Josefina; Parellada, Eduard; Graus, Francesc; Querol, Luis; Dalmau, Josep.

Referencia: Neurology 2022.
Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis

Autores:
Guasp, Mar; Gine-Serven, Eloi; Maudes, Estibaliz; Rosa-Justicia, Mireia; Martinez-Hernandez, Eugenia;

(...)

Saiz, Albert; Graus, Francesc; Castro-Fornieles, Josefina; Parellada, Eduard; Dalmau, Josep.

Referencia: Neurology 2021.
Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDAR encephalitis

Autores:
Mannara, Francesco; Radosevic, Marija; Planaguma, Jesus; Soto, David; Aguilar, Esther;

(...)

Quirk, Michael; Dai, Jing; Gasul, Xavier; Lewis, Mike; Dalmau, Josep.

Referencia: Brain 2020.
LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory

Autores:
Petit-Pedrol, M; Planagumà, J; Mannara, F; Radosevic, M; Sabater, L;

(...)

Dalmau, J; Sell, J; Haselmann, H; Ceanga, M; Geis, C.

Referencia: Brain 2018.
Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis

Autores:
Armangue, Thais; Spatola, Marianna; Vlagea, Alexandru; Mattozzi, Simone; Carceles-Cordon, Marc;

(...)

Alsina, Laia; Saiz, Albert; Rosenfeld, Myrna R; Graus, Francesc; Dalmau, Josep.

Referencia: Lancet Neurology 2018.
Investigations in GABAA receptor antibody-associated encephalitis.

Autores:
Spatola, Marianna; Petit-Pedrol, Mar; Simabukuro, Mateus Mistieri; Armangue, Thas; Castro, Fernanda J;

(...)

Felipe, Ana; Oblitas, Ruben L Caparo; Rosenfeld, Myrna R; Graus, Francesc; Dalmau, Josep.

Referencia: Neurology 2017.
Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice

Autores:
Planagumà, J; Leypoldt, F; Mannara, F; Aguilar, E; Petit-Pedrol, M;

(...)

Martín-García, E; Maldonado, R; Titulaer, MJ; Jain, A; Balice-Gordon, R.

Referencia: Brain 2015.
Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study

Autores:
Titulaer, Maarten J; McCracken, Lindsey; Gabilondo, Inigo; Armangue, Thais; Glaser, Carol;

(...)

Torrents, Abiguei; Saiz, Albert; Rosenfeld, Myrna R; Balice-Gordon, Rita; Dalmau, Josep.

Referencia: Lancet Neurology 2013.

Proyectos destacados

Antibody-mediated NMDA receptor encephalitis: symptoms, biomarkers, and mechanisms of the prolonged recovery stage

Investigador/a principal: Josep Dalmau Obrador

Financiador: Fundación La Caixa

Código: HR22-00221

Duración: 01/12/2022 - 30/11/2025
Investigations in anti-NMDAR encephalitis: New diagnostic test, the role of inflammation in an animal model, and allosteric modulation of NMDAR as a therapeutic strategy

Investigador/a principal: Josep Dalmau Obrador

Financiador: Instituto de Salud Carlos III

Código: PI20/00197

Duración: 01/01/2021 - 31/12/2023
A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor Encephalitis and Assess Markers of Disease

Investigador/a principal: Josep Dalmau Obrador

Financiador: NeuroNext National Institutes of Health USA

Duración: 18/01/2023 - 31/03/2027
Social and Psychological long-term impact of NMDA receptor encephalitis

Investigador/a principal: Josep Dalmau Obrador

Financiador: Instituto de Salud Carlos III

Código: AC21-2/00053

Duración: 01/01/2022 - 31/12/2024

Josep Dalmau

Grupo de investigación

Publicaciones destacadas

Proyectos destacados

Antibody-mediated NMDA receptor encephalitis: symptoms, biomarkers, and mechanisms of the prolonged recovery stage

Investigations in anti-NMDAR encephalitis: New diagnostic test, the role of inflammation in an animal model, and allosteric modulation of NMDAR as a therapeutic strategy

A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor Encephalitis and Assess Markers of Disease

Social and Psychological long-term impact of NMDA receptor encephalitis

Suscríbete a la Newsletter del Clínic